神経因性膀胱に対するProstaglandin F2α誘導体(ONO-995錠)の使用経験

Abstract

The clinical effectiveness of oral administration of ONO-995 tablets was determined in 16 patients with areflexic neurogenic bladders, by means of assessing the improvement of their subjective symptoms, amount of residual urine and cystometric findings. An improvement in subjective symptoms was seen in 7 of the 16 patients, and more than 30% decrease in residual urine in the other 9 patients. An increase in pressure amplitude as evidenced by the difference between the maximum voiding pressure and maximum resting pressure on cystometry was observed in 9 patients. A slight increase in the maximum urethral pressure was observed in 8 of the 13 patients selected for the urethral pressure profile study. These results suggest that ONO-995 increases both urethral resistance and detrusor contraction. When improvement of subjective symptoms showing an increase in pressure amplitude by more than 6cm H2O was evaluated as effective, the effective rate was 43.8%. There was no serious adverse reaction.